Semaglutide is a GLP-1 receptor agonist that suppresses appetite, delays gastric emptying, and improves glucose-dependent insulin secretion
Strongest human evidence The METAOD006 (OPTIONS) Phase 2b trial randomized 502 adults with obesity (BMI 30-45 kg/m^2) to oral AOD-9604 (0.25, 0.5, or 1 mg/day) or placebo for 24 weeks alongside a supervised diet and exercise program
Earlier this week, the FDA added several additional experts to the 20-member panel, including academics who don't have connections to the industry
Treatment Protocols and Frequency B12 treatment plans vary, but most start with a loading phase followed by regular injections
This is particularly valuable for athletes and active individuals who require adequate caloric intake to support training demands, for those following specific dietary protocols that rely on intact hunger cues, or for anyone seeking body composition improvements without the complications of appetite manipulation